Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older

Trial Identifier: 204487
Sponsor: GlaxoSmithKline
Start Date: April 2018
Primary Completion Date: May 2019
Condition: Other - Conditions

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Nova Scotia Truro, Nova Scotia, Canada, B2N 1L2
Canada, Québec Sherbrooke, Québec, Canada, J1L 0H8
Estonia Rakvere, Estonia, 44316
Estonia Tallinn, Estonia, 10117
Estonia Tartu, Estonia, 50106
Germany, Baden-Wuerttemberg Weinheim, Baden-Wuerttemberg, Germany, 69469
Germany, Bayern Wuerzburg, Bayern, Germany, 97070
Germany, Nordrhein-Westfalen Essen, Nordrhein-Westfalen, Germany, 45355
Germany, Nordrhein-Westfalen Goch, Nordrhein-Westfalen, Germany, 47574
Germany, Rheinland-Pfalz Mainz, Rheinland-Pfalz, Germany, 55116
United States, Massachusetts Marlborough, Massachusetts, United States, 01752
United States, North Carolina Salisbury, North Carolina, United States, 28144
United States, South Carolina Spartanburg, South Carolina, United States, 29303